Asset Details
Do you wish to reserve the book?
A T cell resilience model associated with response to immunotherapy in multiple tumor types
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A T cell resilience model associated with response to immunotherapy in multiple tumor types
Do you wish to request the book?
A T cell resilience model associated with response to immunotherapy in multiple tumor types
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A T cell resilience model associated with response to immunotherapy in multiple tumor types
2022
Overview
Despite breakthroughs in cancer immunotherapy, most tumor-reactive T cells cannot persist in solid tumors due to an immunosuppressive environment. We developed Tres (tumor-resilient T cell,
https://resilience.ccr.cancer.gov/
), a computational model utilizing single-cell transcriptomic data to identify signatures of T cells that are resilient to immunosuppressive signals, such as transforming growth factor-β1, tumor necrosis factor-related apoptosis-inducing ligand and prostaglandin E2. Tres reliably predicts clinical responses to immunotherapy in melanoma, lung cancer, triple-negative breast cancer and B cell malignancies using bulk T cell transcriptomic data from pre-treatment tumors from patients who received immune-checkpoint inhibitors (
n
= 38), infusion products for chimeric antigen receptor T cell therapies (
n
= 34) and pre-manufacture samples for chimeric antigen receptor T cell or tumor-infiltrating lymphocyte therapies (
n
= 84). Further, Tres identified
FIBP
, whose functions are largely unknown, as the top negative marker of tumor-resilient T cells across many solid tumor types.
FIBP
knockouts in murine and human donor CD8
+
T cells significantly enhanced T cell-mediated cancer killing in in vitro co-cultures. Further,
Fibp
knockout in murine T cells potentiated the in vivo efficacy of adoptive cell transfer in the B16 tumor model.
Fibp
knockout T cells exhibit reduced cholesterol metabolism, which inhibits effector T cell function. These results demonstrate the utility of Tres in identifying biomarkers of T cell effectiveness and potential therapeutic targets for immunotherapies in solid tumors.
Gene signatures associated with T cell resilience to tumor-derived immunosuppressive signals predict responses to immune-checkpoint inhibitors and adoptive cell therapy and identify
FIBP
as a negative regulator of T cell activity
Publisher
Nature Publishing Group US,Nature Publishing Group
